

AusCann Reinstated on Pershing Securities Trading Cannabis List

13 December 2019 – Leading medicinal cannabis pharmaceutical company **AusCann Group Holdings Limited** (ASX: AC8) ('AusCann' or 'the Company') is pleased to advise that it has been reinstated on Pershing Securities Limited (Pershing) Trading Cannabis List.

The initial restriction followed the decision from Bank of New York Mellon Corp. (BNY Mellon) to restrict trading in US cannabis-related securities. As a result, BNY Mellon's local Pershing unit took a similar stance on a number of ASX-listed cannabis securities, including AusCann.

Pleasingly, after a thorough review, AusCann was confirmed to be fully compliant under the enhanced cannabis securities policy implemented by BNY Mellon and enforced by Pershing. The Company has been added to Pershing's trading cannabis list commencing 12 December 2019.

ENDS

This ASX announcement was authorised for release by the AusCann Group Holdings Board.

For more information, please contact:

For Investment Enquiries

Quentin Megson
Chief Financial Officer
info@auscann.com.au
+61 8 9561 8834

For Media Enquiries

Elodie Castagna
FTI Consulting
elodie.castagna@fticonsulting.com
+61 8 9321 8533

ABOUT AUSCANN

AusCann Group Holdings Limited (ASX:AC8) is an Australian-based pharmaceutical company focused on the development, production, and distribution of cannabinoid-based medicines within Australia and internationally. AusCann transforms the way Medicinal Cannabis is dispensed today by making standardised dose-controlled cannabinoid-based pharmaceutical products and clinical evidence accessible to patients, physicians and healthcare providers. AusCann enables physicians to treat their patients with a reliable, stable and standardised cannabinoid-based pharmaceutical product, monitor treatment results and adjust treatment algorithms using a portfolio of products and formulations.